Posted Nov. 28, 2011 at 12:15 p.m.

Premium Lock Pozen's $75M deal - It's all about cash for product pipeline

Published: 2011-11-28 12:15:00
Updated: 2011-11-28 12:15:00

Treixmet Treximet Image 1 of 2 · Next Image…

The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka...

Read More
Read More

Copyright 2017 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders